Home World News Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients... World News Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 588 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... September 2, 2024 Bus Driver Wears Different Costume Each Day To Make Kids Smile... January 27, 2022 FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and... October 7, 2026 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 Load more HOT NEWS New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic...
